FA
XLRN

FCG Advisors’s Acceleron Pharma XLRN Stock Holding History

FCG Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$428K Buy
3,800
+1,000
+36% +$99.6K 0.1% 107
2020
Q2 		$267K Hold
2,800
– – 0.07% 133
2020
Q1 		$252K Buy
+2,800
New +$218K 0.07% 124

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCG Advisors's XLRN Position: Q3 2020 in Review

FCG Advisors increased its Acceleron Pharma (XLRN) stake by 36% in Q3 2020, buying an estimated $99.6K and bringing the position to 3,800 shares worth $428K. The position accounts for 0.1% of the portfolio, ranked #107.

FCG Advisors first reported a position in XLRN in Q1 2020 and has held it in 3 quarters since. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

  • FCG Advisors held 3,800 shares of Acceleron Pharma worth $428K as of Q3 2020.
  • FCG Advisors bought 1,000 Acceleron Pharma shares in Q3 2020, an estimated $99.6K.
  • Acceleron Pharma made up 0.1% of FCG Advisors's portfolio in Q3 2020, its #107 holding.
  • FCG Advisors first reported a position in Acceleron Pharma in Q1 2020 and has held it in 3 quarters since.
  • 238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on FCG Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.